Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | SIK1 | P57059 | 1/20 | 0.34 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186649 | 0.93 | PTPN11 (0.43) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL16186645 | 0.90 | PTPN11 (0.41) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL16186641 | 0.89 | PTPN11 (0.42) | PTPN11PIM1PIM2BTKITK | |
| SCHEMBL16186668 | 0.89 | PTPN11 (0.41) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL16186647 | 0.88 | PTPN11 (0.41) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL16186665 | 0.85 | PTPN11 (0.41) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL15805188 | 0.85 | PTPN11 (0.43) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL15805448 | 0.85 | PTPN11 (0.41) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL16186653 | 0.85 | PTPN11 (0.40) | PTPN11PIM1PIM2PIK3CABTK | |
| SCHEMBL15805191 | 0.83 | PTPN11 (0.39) | PTPN11PIM1PIM2HTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834551-B2 | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-02-18 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206188-B2 | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2014172513-A2 | 3,5-(UN)SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE, 1H-PYRAZOLO[3,4-B]PYRIDINE AND 5H-PYRROLO [2-,3-B]PYRAZINE DUAL ITK AND JAK3 KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046627-A1 | ITK and JAK Kinase Inhibitors | JAK3, ITK, JAK2 | PTPN11 947/4885PIM1 700/4885PIM2 626/4885 |
| US-20140315909-A1 | 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors | JAK3, TYK2, JAK2 | PTPN11 476/4885PIM1 793/4885PIM2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.